Scaling Privacy-First AI: Inside the OncoAgent Dual-Tier Multi-Agent Framework

The integration of Artificial Intelligence into clinical oncology represents one of the most significant frontiers in modern medicine. However, the deployment of Large Language Models (LLMs) in healthcare is perpetually throttled by a fundamental tension: the need for high-performance reasoning versus the absolute necessity of patient data privacy.

At the recent lablab.ai AMD Developer Hackathon, a new framework emerged to address this bottleneck. OncoAgent is a dual-tier multi-agent system designed specifically for privacy-preserving oncology clinical decision support [1]. By utilizing a sophisticated orchestration layer and leveraging local hardware optimization, OncoAgent demonstrates how agentic workflows can navigate the complexities of HIPAA compliance while providing expert-level diagnostic assistance.

The Challenge: Privacy vs. Performance in Medical AI

Building AI agents for oncology is significantly more complex than building general-purpose assistants. Oncology requires synthesizing vast amounts of unstructured data—pathology reports, genomic sequences, and longitudinal patient histories—while adhering to strict regulatory frameworks.

Standard cloud-based LLM API calls pose a risk of data leakage. Conversely, fully local “small” models often lack the medical reasoning depth required for complex clinical decisions. OncoAgent solves this by splitting the cognitive workload into two distinct tiers, ensuring that sensitive Patient Health Information (PHI) never leaves the local secure environment [1].

The Dual-Tier Architecture: How OncoAgent Operates

The core innovation of OncoAgent lies in its Dual-Tier Multi-Agent Framework. Rather than relying on a single monolithic model, the system distributes tasks across specialized agents categorized into two distinct operational layers.

Tier 1: The Local Privacy Tier

The first tier resides entirely on the local “Agent Rig.” These agents are the front line of data security, responsible for handling raw patient data before it is ever processed for high-level reasoning. Their primary functions include:

  • Data De-identification: Automatically stripping PHI (names, addresses, IDs) from clinical notes.
  • Local Feature Extraction: Summarizing dense medical history into high-level clinical tokens that describe the pathology without identifying the individual.
  • Secure Retrieval: Interfacing with local vector databases containing specific hospital protocols or private patient records.

By keeping these tasks local, OncoAgent ensures that the “Identity” of the patient is decoupled from the “Medical Case” being analyzed [1].

Tier 2: The Global Knowledge Tier

Once data is anonymized, it is passed to the second tier. This tier utilizes more powerful, potentially cloud-hosted or larger local models that have been fine-tuned on massive medical datasets. These agents focus on:

  • Cross-Reference Reasoning: Comparing the de-identified case against global oncology literature and clinical trial databases.
  • Treatment Optimization: Suggesting evidence-based chemotherapy or immunotherapy regimens based on the latest peer-reviewed studies.
  • Consensus Building: A “Multi-Agent Debate” mechanism where different agent personas (e.g., an Oncologist Agent, a Radiologist Agent, and a Pathologist Agent) discuss the case to reach a refined conclusion.

Hardware Optimization: The Role of AMD and ROCm

Because OncoAgent was developed within the context of an AMD Developer Hackathon, its technical foundation is heavily optimized for AMD’s hardware ecosystem. For builders of AI agent rigs, this highlights a shift away from the NVIDIA-only paradigm toward high-VRAM alternatives.

Leveraging AMD ROCm

The framework utilizes the AMD ROCm (Radeon Open Compute) platform to accelerate local inference [1]. For oncology agents, low-latency local processing is critical. Using ROCm-compatible libraries allows the Tier 1 agents to run on consumer-grade hardware like the Radeon RX 7900 XTX or professional-grade Instinct MI series accelerators with high throughput.

Hardware ComponentRecommended Specification for OncoAgentPurpose
GPUAMD Radeon RX 7900 XTX (24GB VRAM)Local inference of 7B-30B parameter models for Tier 1.
Memory64GB+ DDR5Handling large vector databases of medical literature.
StorageNVMe Gen4/Gen5 SSDRapid retrieval of local RAG (Retrieval-Augmented Generation) data.
Software StackROCm 6.0+, PyTorch, LangChainOrchestration and hardware acceleration.

The use of high-VRAM AMD cards is particularly beneficial for OncoAgent because medical RAG often involves long context windows. When processing a patient’s entire 10-year history, the agent needs to maintain a significant amount of data in active memory to avoid context truncation or “forgetting” critical historical data points.

The Multi-Agent Orchestration Workflow

The efficiency of OncoAgent isn’t just about the hardware; it’s about the orchestration. The framework uses a structured pipeline to move from a raw clinical query to a final decision support summary:

  1. Input Categorization: An “Intake Agent” identifies the type of oncology case (e.g., Breast Cancer, Lung Cancer).
  2. Task Decomposition: The system breaks the query into sub-tasks (e.g., “Analyze tumor markers,” “Check drug-drug interactions”).
  3. Parallel Execution: Tier 1 agents extract local data while Tier 2 agents prepare global knowledge modules.
  4. Synthesis & Validation: A “Critic Agent” reviews the proposed treatment plan for inconsistencies or medical hallucinations before presenting it to the human clinician [1].

This “Criticism” loop is vital. In oncology, a hallucination isn’t just a bug; it’s a potential safety risk. By having multiple agents cross-verify each other’s outputs, OncoAgent increases the reliability of the final output.

Why This Matters for Agent Builders

The OncoAgent framework provides a blueprint for building agents in any highly regulated industry, such as finance, law, or defense. The “Dual-Tier” approach is a masterclass in balancing privacy with power.

For builders, the takeaway is clear: the future of professional AI rigs lies in hybrid deployments. We are moving away from the “all-in-the-cloud” or “all-local” extremes. Instead, successful rigs will be designed to handle local de-identification and secure RAG, while selectively “bursting” to more powerful models for complex reasoning.

Furthermore, the success of OncoAgent on AMD hardware proves that the ROCm ecosystem is maturing. Builders can now realistically look at AMD’s high-VRAM offerings as viable alternatives to NVIDIA for running complex, multi-agent medical frameworks [1].

Future Directions: Federated Learning and Edge Deployment

The developers of OncoAgent have signaled that the framework could eventually evolve into a federated system. In this scenario, multiple hospitals could contribute to the “Global Knowledge” of Tier 2 without ever sharing their “Local Private” Tier 1 data. This would create a collective intelligence that grows more accurate with every cancer case treated, while maintaining absolute patient confidentiality.

For the hardware enthusiast, this means the demand for local AI compute in clinical settings is only going to increase. The “Onco-Rig” of the future may well be a standard fixture in every oncology department, acting as a secure gateway between local patient care and global medical expertise. By combining high-performance local GPUs with sophisticated agentic orchestration, OncoAgent isn’t just a hackathon project—it’s a glimpse into the future of private, professional-grade AI.

Sources & Further Reading